Repository logo
Communities & Collections
Research Outputs
Fundings & Projects
People
Statistics
User Manual
Have you forgotten your password?
  1. Home
  2. Ss. Cyril and Methodius University in Skopje
  3. UKIM 02: Dissertations from the Doctoral School / Дисертации од Докторската школа
  4. Интравитреален антиангиоген третман на макуларен едем заради ретинални венски оклузии
Details

Интравитреален антиангиоген третман на макуларен едем заради ретинални венски оклузии

Date Issued
2017
Author(s)
Ивановска Аџиевска, Билјана
Abstract
Aim: To evaluate the one-year efficacy and safety of intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions. Methods: Interventional, prospective study of patients with macular edema due to central or branch retinal vein occlusion (CRVO or BRVO), followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 microns received intravitreal injection of bevacizumab. After 1 month BCVA and OCT macula images were recorded. In patients with less than 30% improvement in BCVA and CMT 2 more injections were applied at 1.5-month intervals. In all other patients further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed. Results: 33 eyes with CRVO and 55 eyes with BRVO were treated. After 1 year 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 logMAR units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (p=0.001), from baseline 1.2±0.95 logMAR to 0.75±0.6 at 1-year. Significant improvement of mean BCVA (p<0.001) was also found in BRVO, from baseline 0.71±0.75 to 0.28±0.5 at 1 year. Baseline CMT was 852.21±298.20 μm for CRVO and 597.95±185.63 μm for BRVO. In both groups there was significant decrease (p<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral in 49.1% of eyes with BRVO. Conclusion: In macular edema due to RVO, intravitreal anti-angiogenic treatment provides sustained improvement in visual acuity and macular edema reduction within high percentage of treated eyes after 1 year of follow-up.
Subjects

macular edema, retina...

File(s)
Loading...
Thumbnail Image
Name

S-BiljanaIvanovskaAdzijevska2017.pdf

Size

3.55 MB

Format

Adobe PDF

Checksum

(MD5):c2b28a507d1ed49791ead28565db026d

⠀

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify